Metraipolis › archive › dc_ddab0dffe5ba

Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with rheumatoid arthritis: a 12-month observational study — Europe PMC PMID:41074195

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41074195
DOI
10.1186/s42358-[numero omesso]-5
License (as archived)
solo-consultazione
Archived
2026-11-09T10:08:51.518Z
SHA-256 of the archived text
0bde03048e03480bdefb65ba4b649207a5736b6986e86bd2e38f57b3122406c9
Stable URL of this page
https://metraipolis.com/documento/dc_ddab0dffe5ba

How to cite

Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with rheumatoid arthritis: a 12-month observational study — Europe PMC PMID:41074195 — Europe PMC (en), https://europepmc.org/article/MED/41074195 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ddab0dffe5ba (Metraipolis archive dc_ddab0dffe5ba, sha256 0bde03048e03480bdefb65ba4b649207a5736b6986e86bd2e38f57b3122406c9)
BibTeX
@misc{dcddab0dffe5ba,
  title = {Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with rheumatoid arthritis: a 12-month observational study — Europe PMC PMID:41074195},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41074195},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ddab0dffe5ba; sha256 0bde03048e03480bdefb65ba4b649207a5736b6986e86bd2e38f57b3122406c9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41074195. Agents can read the archived copy with the MCP tool read_document.